Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10529 in KRAS G12D advanced solid tumors
NCT06963398Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of HS-10529 in solid tumor (advanced stage), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Maximum Tolerated Dose or Maximum Applicable Dose up to 24 months. Planned start May 2025; status: not yet recruiting.
02
Drugs
HS-10529
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06963398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963398.